The Journal of Allergy and Clinical Immunology
Volume 120, Issue 3 , Pages 586-593 , September 2007

IFN-γ–induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations

  • Peter A.B. Wark, BMed, PhD

      Affiliations

    • Brooke Laboratories, University of Southampton, Southampton, United Kingdom
    • Department of Respiratory and Sleep Medicine, John Hunter Hospital, University of Newcastle, Newcastle, Australia
    • Corresponding Author InformationReprint requests: Peter A. B. Wark, BMed, PhD, Department of Respiratory and Sleep Medicine, John Hunter Hospital, Locked Bag 1 HRMC, NSW 2310, Australia.
    • ,
  • Fabio Bucchieri, MD

      Affiliations

    • Department of Experimental Medicine, Human Anatomy Division, University of Palermo, Palermo, Italy
    • ,
  • Sebastian L. Johnston, MD, PhD

      Affiliations

    • Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    • ,
  • Peter G. Gibson, MBBS

      Affiliations

    • Department of Respiratory and Sleep Medicine, John Hunter Hospital, University of Newcastle, Newcastle, Australia
    • ,
  • Lynnsey Hamilton, BSci, PhD

      Affiliations

    • Brooke Laboratories, University of Southampton, Southampton, United Kingdom
    • ,
  • Joanna Mimica

      Affiliations

    • Department of Respiratory and Sleep Medicine, John Hunter Hospital, University of Newcastle, Newcastle, Australia
    • ,
  • Giovanni Zummo, MD

      Affiliations

    • Department of Experimental Medicine, Human Anatomy Division, University of Palermo, Palermo, Italy
    • ,
  • Stephen T. Holgate, FRCP

      Affiliations

    • Brooke Laboratories, University of Southampton, Southampton, United Kingdom
    • ,
  • John Attia, MD, PhD

      Affiliations

    • Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, Australia
    • ,
  • Ammarin Thakkinstian, MD

      Affiliations

    • Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, Australia
    • Clinical Epidemiology Unit, Mahidol University, Bangkok, Thailand
    • ,
  • Donna E. Davies, PhD

      Affiliations

    • Brooke Laboratories, University of Southampton, Southampton, United Kingdom

Received 16 February 2007 ,Revised 18 April 2007 ,Accepted 19 April 2007.

  • Image Result

    Serum IP-10 levels at presentation with acute asthma. Data are summarized by box plots: boxes represent the 25th and 75th percentiles, the central line represents the median, and solid circles represe

    Serum IP-10 levels at presentation with acute asthma. Data are summarized by box plots: boxes represent the 25th and 75th percentiles, the central line represents the median, and solid circles represent outliers. Subjects with acute virus-induced asthma are represented by colored boxes, and those with non–virus-induced acute asthma are represented by open boxes. Those with acute virus-induced asthma had significantly increased median serum IP-10 levels (604 pg/mL [interquartile range, 450-1536.3]) compared with those with non–virus-induced acute asthma (167 pg/mL [interquartile range, 141.5-168], P < .001). Comparison between groups was analyzed by using the Mann-Whitney U test.

 Supported by the British Medical Association HC Roscoe fellowship and Asthma UK. Dr Wark was funded by the National Health and Medical Research Council of Australia on a Neil Hamilton Fairley traveling fellowship.

 Disclosure of potential conflict of interest: P. A. B. Wark has consultant arrangements with AstraZeneca, has a patent licensing arrangement from antivirus therapy for respiratory diseases, and receives grants/research support from Biota Pty, Ltd. S. L. Johnston has consultant arrangements with AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MedImmune, Merck, Pfizer, Sanofi-Aventis, Schering-Plough, and Synairgen; has patent licensing arrangements for transgenic animal models of HRV with human intercellular adhesion molecule 1 sequences, antivirus therapy for respiratory diseases, and the use of IFN-λ for the treatment and prevention of virally induced exacerbation in asthma and chronic pulmonary obstructive disease; and receives grants/research support from AstraZeneca, Centocor, GlaxoSmithKline, Pfizer, and Merck. S. T. Holgate has consultant arrangements with Synairgen, Novartis, Merck, Cambridge Antibody Technology, Almiral, and Rotta; owns stock in Synairgen; receives grant support from Novartis and UCB; and is on the speakers' bureau for Novartis and Merck. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(07)01025-1

doi: 10.1016/j.jaci.2007.04.046

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 3 , Pages 586-593 , September 2007

Article Tools

* Image Usage & Resolution